KIMBERLY DRAKE: Open Payments
NPI 1174580245 · MARRERO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,417 in 90 payments from 16 companies in 2025. Trend: 2023 $640 · 2024 $1,342 · 2025 $1,417
Food & beverage: $1,417
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $217 |
| Janssen Biotech, Inc. | 15 | $217 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $183 |
| Ardelyx, Inc. | 8 | $169 |
| Celltrion USA Inc. | 6 | $110 |
| Gilead Sciences, Inc. | 3 | $77 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| Aimmune Therapeutics, Inc. | 3 | $60 |
| ABBVIE INC. | 3 | $57 |
Products named: TREMFYA, ENTYVIO, XIFAXAN, IBSRELA, VEGZELMA, IQIRVO, DUPIXENT, ZENPEP.
Industry payments across LA — which companies pay providers there.
